Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Phase of Trial: Phase I/II
Latest Information Update: 23 Apr 2017
At a glance
- Drugs REP 2139-Ca (Primary) ; Peginterferon alfa-2a; Thymalfasin
- Indications Hepatitis B
- Focus Adverse reactions; Proof of concept
- Sponsors REPLICor
- 07 Jun 2016 Results published in the journal PLOS ONE, according to a REPLICor media release.
- 07 Jun 2016 Results published in a REPLICor media release.
- 10 Apr 2015 According to a REPLICor media release, the updated data from this and another trial will be presented at the 2015 Lancet Viral Hepatitis Conference.